FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy.
👑 Is deeper B-cell depletion enough to claim the throne?
📖 Check out the latest Visual Abstract by Dr Divya Bajpai
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa primaria.
👑 ¿Será suficiente una depleción más profunda de células B para reclamar el trono?
📖 Revisa el más reciente resumen visual elaborado por la Dra Divya Bajpai
El estudio REGENCY, un ensayo fase 3, doble ciego y controlado con placebo, evaluó la eficacia y seguridad de obinutuzumab en pacientes con nefritis lúpica activa. ¿Es realmente eficaz y seguro en la depleción de células B en LN?
🔥 Hoy en #NephJC analizamos cómo estos hallazgos impactarán el futuro del tratamiento en la nefritis lúpica. 🕘 Únete a la discusión a las 9 pm EST en BlueSky🦋!
Is Obinutuzumab Effective and Safe in Active Lupus Nephritis? Check out the beautiful VA by NSMC Faculty Dr Divya Bajpai on the REGENCY Trial, answering the same.
